Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative.

Intracranial metastases (ICM), specifically parenchymal brain metastases, remain a major clinical challenge in solid tumor oncology, despite recent advances in cancer therapies which have led to improvements in survival for these patients. Improving outcomes even further in this patient population will require a multi-disciplinary approach, including pre-clinical and translational studies, clinical trials, and studies of patient reported outcomes and quality of life. At the 2023 and 2024 joint Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) CNS Metastases Conferences, two ICM collaborative group think tanks convened, composed of diverse, multi-disciplinary stakeholders, including basic and translational researchers, clinical trialists, and clinicians from academia and the community setting. Here we summarize the key knowledge gaps and consensus recommendations put forth by these two think tanks. Advances in ICM research and improvements in patient outcomes will require close inter-specialty and inter-institutional collaboration between stakeholders, including pre-clinical and translational researchers, clinical investigators, industry, and regulatory bodies.